Trial Information

Summary: Prostate Cancer Study CEPO906A2229

Novartis Oncology is conducting a clinical research study to evaluate the difference in effectiveness and safety between the study drug patupilone plus prednisone and the drug docetaxel, in people who have hormone refractory prostate cancer. The reason for this study is to find out which of these two medicines gives better relief of prostate cancer. Patupilone is a medicine which has not been approved by the FDA (US Food and Drug Administration) for the treatment of people with prostate cancer. Docetaxel is a medication approved by the FDA to treat breast cancer, non-small cell lung cancer and prostate cancer.

Participants will visit the study site approximately once every three weeks for treatment and evaluations for 20 weeks. Each visit should take about 1-3 hours. If a participant has been discontinued from treatment for a reason other than progression of disease, they are required to visit the study site every three weeks for disease evaluation and every six weeks for radiological scans until progression of disease is documented.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: November 21, 2008 at 2:56:07 PM